Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lacrimation increased06.08.02.0040.003476%
Laryngeal pain22.02.05.036--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukoderma23.05.02.001--Not Available
Leukopenia01.02.02.0010.003476%Not Available
Lichen planus23.03.08.0010.003476%Not Available
Linear IgA disease10.04.02.006; 23.03.01.0150.003476%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.002317%Not Available
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.004--Not Available
Low set ears04.06.01.002; 03.13.01.002--Not Available
Lymphadenopathy01.09.01.0020.002317%Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malaise08.01.01.0030.008110%
Malignant melanoma23.08.01.001; 16.03.01.0010.002317%Not Available
Mania19.16.02.0020.004634%
Metastatic malignant melanoma23.08.01.002; 16.03.01.0020.001209%Not Available
Migraine17.14.02.001; 24.03.05.003--Not Available
Mouth ulceration07.05.06.0040.004634%Not Available
Mucosal ulceration08.01.06.003--Not Available
Multiple sclerosis17.16.01.001; 10.04.10.008--Not Available
Musculoskeletal pain15.03.04.0070.002317%
Myalgia15.05.02.0010.006952%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.017379%
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutrophil count decreased13.01.06.010--
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages